FORTE BIOSCIENCES FBRX 深 沪
等待开盘 11-01 09:30:00 美东时间
12.94
-0.330
-2.49%
华盛通- 最 高13.5674
- 今 开13.27
- 成交量 6.42万股
- 最 低 12.65
- 昨 收 13.27
- 总市值 1.61亿
- 52周最高 28.68
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 4.8119
- 委 比 0.00%
- 总股本 1243.29万
- 历史最高 6732.375
- 量 比 0.48
- 振 幅 6.91%
- 历史最低 4.90
- 每 手 1
- 风险率 4.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Forte Biosciences Highlights FB102's Efficacy in Celiac Disease at Tampere Symposium, Underscoring Histological Protection and Symptom Relief in Phase 1b Study
Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune
09-15 21:09
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroBiologics, Inc., a clinical-stage biotech company developing therapies for chronic diseases using fibroblast cells, announced that CEO Pete O’Heeron will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10 in New York City. The company will deliver a presentation on September 10 at 12:00 p.m. ET and hold one-on-one investor meetings during the event. For more information, visit FibroBiologics’ website or...
08-27 12:30
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
08-15 20:11
Forte Biosciences Announces Public Offering of Shares
Forte Biosciences ( ($FBRX) ) just unveiled an update. On June 24, 2025, Forte ...
06-26 05:19
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Forte Biosciences launches public offering
Forte Biosciences (NASDAQ:FBRX) has initiated an underwritten public offering of common stock and pre-funded warrants. Certain investors may receive pre-funded warrants instead of common stock. Underw...
06-25 04:16
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
06-24 20:00
Forte Biosciences Reports Results in Celiac Disease Trial, Paving Way for Phase 2 in 2026
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac
06-23 19:20
Forte Biosciences Elects New Directors at Annual Meeting
Forte Biosciences ( ($FBRX) ) has provided an update. On May 29, 2025, Forte Bi...
05-30 20:58
